Marquette Asset Management LLC Buys Shares of 51,080 Metagenomi, Inc. (NASDAQ:MGX)

Marquette Asset Management LLC purchased a new stake in shares of Metagenomi, Inc. (NASDAQ:MGX) during the fourth quarter, Holdings Channel reports. The fund purchased 51,080 shares of the company’s stock, valued at approximately $184,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in MGX. Rhumbline Advisers bought a new position in Metagenomi in the 2nd quarter valued at approximately $26,000. BNP Paribas Financial Markets increased its position in Metagenomi by 130.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,799 shares of the company’s stock valued at $28,000 after acquiring an additional 7,256 shares during the period. Virtu Financial LLC acquired a new position in Metagenomi in the 3rd quarter valued at approximately $33,000. XTX Topco Ltd bought a new position in shares of Metagenomi during the second quarter valued at $66,000. Finally, Green Alpha Advisors LLC acquired a new position in shares of Metagenomi during the third quarter worth $69,000.

Analyst Upgrades and Downgrades

MGX has been the subject of a number of recent research reports. HC Wainwright increased their price objective on Metagenomi from $7.00 to $14.00 and gave the company a “buy” rating in a report on Tuesday, December 10th. Chardan Capital reissued a “buy” rating and issued a $15.00 price target on shares of Metagenomi in a research note on Wednesday, November 20th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $16.67.

Metagenomi Stock Down 5.2 %

Shares of MGX opened at $2.76 on Wednesday. The firm’s fifty day simple moving average is $2.82 and its two-hundred day simple moving average is $2.97. Metagenomi, Inc. has a 12 month low of $1.61 and a 12 month high of $12.74.

Metagenomi Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.